Compare AstraZeneca plc (AZN) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs D R Horton Inc — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while D R Horton Inc trades at $146.27 (market cap $42.18B). The key difference: AstraZeneca plc is far larger — about 5.9× D R Horton Inc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | DHI | |
|---|---|---|
Market Cap | $248.14B | $42.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $184.04 |
52-Week Low | $147.06 | $132.53 |
Enterprise Value | $275.41B | $47.28B |
Dividend Yield | 2.01% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
D.R. Horton (DHI) trades at $146.44, down slightly by 0.15% today, with a bullish technical signal from moving averages. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance due to soft demand. Valuation metrics appear reasonable with a P/E of 14.37 and P/S of 1.31, while profitability margins have compressed over recent years.
The outlook is mixed: strong cash flow and execution support the stock, but elevated mortgage rates and weak homebuying trends pose headwinds. Analyst consensus is a Buy with a $153 price target, indicating modest upside potential, though risks from housing market volatility persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
